The researchers, however, noted that with Delta, Pfizer-BioNTech vaccine and Oxford-AstraZeneca preventive, known as Covishield in India, still offer good protection against new infections.
Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 before through natural infection, they said.
The Centre for Disease Control and Prevention (CDC) has now issued a Level 2 Travel Health Notice for India due to COVID-19, indicating a moderate level of COVID-19 in the country.
At the same time, the State Department urged Americans not to travel to Jammu and Kashmir (except the eastern Ladakh region and its capital, Leh) due to terrorism and civil unrest.
According to CARE Ratings, the majority of domestic demand is expected to be fulfilled by March 2022, when the export opportunities in the high-income markets such as Europe, North America, and developed Asian countries are likely to be completely exhausted.
However, the export opportunities in various African, Asian excluding China and Japan and some South American countries, where the pace of vaccination remains very slow would still exist, which is expected to remain greater than 1.25 billion doses, it said.
While vaccine breakthroughs offer hope, a return to mass travel remains many months away, airlines say. Some will struggle to make it through the northern hemisphere winter, when profits are thin even in normal times.
The EU could pay more than $10 billion to buy hundreds of millions of doses of the vaccine jointly developed by Pfizer Inc. and BioNTech as well as that of CureVac NV, Reuters said Friday, citing an EU official it didn’t name. The price it agreed for the Pfizer-BioNTech shot is 15.50 euros ($18.34) per dose, less than what the U.S. is paying, the newswire said.
Supporters of the waiver say existing intellectual property (IP) rules create barriers on access to affordable medicines and vaccines and they want restrictions to be eased, as they were during the AIDS epidemic.
“This is really good news, because we can be confident that, at least in the short term, most people who get COVID-19 won’t get it again,” said David Eyre, a professor at Oxford’s Nuffield Department of Population Health, who co-led the study.
The COVID-19 case fatality rate has further declined to 1.46 per cent.There are 4,43,794 active cases of coronavirus infection in the country which comprises 4.92 per cent of the total caseload, the data stated
According to the ICMR, a cumulative total of 12,95,91,786 samples have been tested up to November 20 with 10,83,397 samples being tested on Thursday
The result is that India’s Covid-19 cases are likely much higher than the national numbers. Health experts fear new infection waves as the country gathers to celebrate a season of weddings and Hindu festivals amid a smoggy winter in the densely populated north.
The vaccine would be priced between $5-$6 in the retail market, but the Indian government would get it for much less, because they would buy it bulk, Adar Poonawaala, the chief executive of the SIIs aid.
“Releasing backend code will help people in understanding the complete functioning of the app. This will clear any doubt that they have regarding privacy and security of their data,” a MeitY official explained.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Dr Albert Bourla, Pfizer Chairman and CEO
There are 4,43,303 active cases of coronavirus infection in the country as on date which accounts for 4.95 per cent of the total caseload, the data stated
The total recoveries have surged to 83,83,602, pushing the national recovery rate to 93.58?per cent, while the COVID-19?case?fatality rate stands at 1.47 per cent